Humana (NYSE:HUM) Cut to Equal Weight at Stephens

Humana (NYSE:HUM) was downgraded by equities research analysts at Stephens from an “overweight” rating to an “equal weight” rating in a report issued on Wednesday, Briefing.com reports. They currently have a $250.00 price target on the insurance provider’s stock, down from their previous price target of $400.00. Stephens’ target price indicates a potential downside of 10.53% from the company’s current price.

Several other research firms also recently issued reports on HUM. JPMorgan Chase & Co. lifted their price objective on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a report on Wednesday, August 21st. Morgan Stanley started coverage on shares of Humana in a report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 target price on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $395.00 target price on shares of Humana in a report on Tuesday. Truist Financial upped their price target on shares of Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, July 15th. Finally, Royal Bank of Canada lifted their price objective on shares of Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. Fourteen analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $389.70.

Humana Trading Down 11.8 %

HUM opened at $279.42 on Wednesday. The firm’s 50 day moving average is $346.44 and its 200-day moving average is $343.73. Humana has a 52-week low of $276.80 and a 52-week high of $530.54. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $33.67 billion, a P/E ratio of 17.40, a P/E/G ratio of 2.44 and a beta of 0.50.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm’s revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $8.94 EPS. Analysts expect that Humana will post 16.01 EPS for the current fiscal year.

Institutional Trading of Humana

Several large investors have recently made changes to their positions in the stock. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Humana by 110.7% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 40,400 shares of the insurance provider’s stock worth $15,095,000 after purchasing an additional 21,225 shares during the last quarter. University of Texas Texas AM Investment Management Co. raised its position in shares of Humana by 1,219.0% in the second quarter. University of Texas Texas AM Investment Management Co. now owns 1,319 shares of the insurance provider’s stock valued at $493,000 after purchasing an additional 1,219 shares during the period. Sanctuary Advisors LLC bought a new stake in shares of Humana during the 2nd quarter worth $3,341,000. Clear Rock Advisors LLC grew its stake in Humana by 2.3% in the 2nd quarter. Clear Rock Advisors LLC now owns 5,250 shares of the insurance provider’s stock valued at $1,962,000 after buying an additional 119 shares during the last quarter. Finally, Heritage Oak Wealth Advisors LLC bought a new position in Humana in the 2nd quarter worth $3,456,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.